Two phase 3 trials of gantenerumab in early Alzheimer's disease
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer's disease. METHODS: We conducted two phase 3 trials (GRADUATE I and II) involving participants 50 to 90 years of age with mild cognitive impairment or mild dementia due to Alzheimer's disease and evidence of amyloid plaques on positron-emission tomography (PET) or cerebrospinal fluid (CSF) testing. Participants were randomly assigned to receive gantenerumab or placebo every 2 weeks. The primary outcome was the change from baseline in the score on the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB; range, 0 to 18, with higher scores indicating greater cognitive impairment) at week 116. RESULTS: A total of 985 and 980 participants were enrolled in the GRADUATE I and II trials, respectively. The baseline CDR-SB score was 3.7 in the GRADUATE I trial and 3.6 in the GRADUATE II trial. The change from baseline in the CDR-SB score at week 116 was 3.35 with gantenerumab and 3.65 with placebo in the GRADUATE I trial (difference, -0.31; 95% confidence interval [CI], -0.66 to 0.05; P = 0.10) and was 2.82 with gantenerumab and 3.01 with placebo in the GRADUATE II trial (difference, -0.19; 95% CI, -0.55 to 0.17; P = 0.30). At week 116, the difference in the amyloid level on PET between the gantenerumab group and the placebo group was -66.44 and -56.46 centiloids in the GRADUATE I and II trials, respectively, and amyloid-negative status was attained in 28.0% and 26.8% of the participants receiving gantenerumab in the two trials. Across both trials, participants receiving gantenerumab had lower CSF levels of phosphorylated tau 181 and higher levels of Aβ42 than those receiving placebo; the accumulation of aggregated tau on PET was similar in the two groups. Amyloid-related imaging abnormalities with edema (ARIA-E) occurred in 24.9% of the participants receiving gantenerumab, and symptomatic ARIA-E occurred in 5.0%. CONCLUSIONS: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline. (Funded by F. Hoffmann-La Roche; GRADUATE I and II ClinicalTrials.gov numbers, NCT03444870 and NCT03443973, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two phase III trials (NCT03444870 and NCT03443973) were recently terminated. In these trials, when assessing the efficacy and safety of gantenerumab (19) in participants with early (prodromal to mild) AD, the drug showed little clinical benefit in slowing cognitive decline, potentially due to limited clearance of amyloid plaques, with 5.0% participants experienced amyloid-related imaging abnormal”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [461]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Self-citation
Cited by
Items 101–200 of 312
Teipel, S. J., Tang, Y., & Khachaturian, A. S. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70155 · Cited by 19
“1.”
Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach
Haut, F., Argyrousi, E. K., & Arancio, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010259 · Cited by 11
“For instance, treatment with gantenerumab, a fully human anti-A β monoclonal antibody, reduced levels of amyloid plaques after 116 weeks of treatment, but did not improve cognitive performance in patients with early AD [103].”
BackgroundAmyloid-Directed Antibodies: Past, Present, and Future
Noorda, K., Noorda, K. J., Sabbagh, M. N., Bertelson, J. A., Singer, J., & Decourt, B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240189 · Cited by 11
In Vivo Head-to-Head Comparison of [18F]GTP1 with [18F]MK-6240 and [18F]PI-2620 in Alzheimer Disease
Olafson, E., Tonietto, M., Klein, G., Teng, E., Stephens, A. W., Russell, D., Pickthorn, K., & Bohorquez, S. M. S. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268623 · Cited by 10
Self-citationA Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., Initiative, A. D. N., Weiner, M. W., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213490 · Cited by 10
Self-citationProteostasis and Neuroinflammation in Alzheimer’s Disease
Potokiri, A., & Wang, H. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin39826 · Cited by 10
Alzheimer's disease: from molecular pathways to therapies
Feng, J.-Q., Yang, L.-L., Ya-xi, L., & Yao, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00443-2 · Cited by 11
“Gantenerumab, a fully human, subcutaneously administered anti-Aβ IgG1 antibody with high affinity for aggregated Aβ, including oligomers and fibrils, showed limited efficacy in early symptomatic AD [274].”
Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
Wang, H., Yan, X., Zhang, Y., Wang, P., Li, J., & Zhang, X. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230139 · Cited by 9
Gantenerumab for early Alzheimer’s disease: a systematic review and meta-analysis
de Almeida, A. M., Leite, M. G. H. S. J., Lopes, L. M., Lima, P. L. G., Barros, M. L. S., Pinheiro, S. L. R., Andrade, Í. B., Viana, P., Morbach, V., Marinheiro, G., et al. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2367016 · Cited by 12
“All included studies reported data on CDR-SB, but only three were suitable for statistical analysis [19,20].”
Okonkwo, O. C., Mindt, M. R., Weiner, M. W., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14186 · Cited by 9
Squitti, R., Pal, A., Ivanova, I. D., Marianetti, M., & Rongioletti, M. C. A. (2025) · Biomolecules · doi:10.3390/biom15060788 · Cited by 9
“Among the available anti-amyloid agents, Donanemab has shown the strongest clinical effect [2], while Gantenerumab, despite achieving amyloid clearance, failed to meet its primary efficacy endpoints [3].”
Pascual‐Lucas, M., Lacosta, A. M., Montañés, M., Canudas, J., Loscos, J., Monleón, I., Allué, J. A., Sarasa, L., Fandos, N., Romero, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70776 · Cited by 13
Self-citationLin, M., Zeng, Q., Zhong, S., Nie, S., Zhang, R., Hong, H., Liu, L., Wang, S., Li, K., Luo, X., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213953 · Cited by 14
Abushakra, S. R., Doraiswamy, P. M., Hey, J. A., Tosun, D., Barkhof, F., Barakos, J. A., Petrella, J. R., Kesslak, J. P., Power, A., Sabbagh, M. N., et al. (2025) · CNS Drugs · doi:10.1007/s40263-025-01251-y · Cited by 16
“The two identical gantenerumab phase 3 trials were of 24 months duration, and the datapoints were normalized to 18 months and plotted [53, 54].”
InfluentialSelf-citationDefining patient‐centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease
Zhu, Z., Steward, A., Dehsarvi, A., Roemer, S. N., Dewenter, A., Biel, D., Hirsch, F., Frontzkowski, L. K., Pescoller, J., Klonowski, M., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71064 · Cited by 8
“15,16 Here, removal of A β with lecanemab or donanemab has yielded up to 35% delay of cognitive decline, 8,11,17 while gantenerumab showed no clinical benefit 10 and aducanumab yielded inconsistent results across two trials.”
MRI-to-PET synthesis via deep learning for amyloid-β quantification in Alzheimer’s disease
Chen, Z., Bi, S., Yi, S., Wang, F., Wang, Y., Qi, Z.-Y., Wang, T., Li, X., Li, S.-N., Xiao, H., et al. (2026) · European Radiology · doi:10.1007/s00330-025-12251-3 · Cited by 12
Wang, G., Hassenstab, J. J., Li, Y., Aschenbrenner, A. J., McDade, E., Llibre‐Guerra, J. J., Bateman, R. J., & Xiong, C. (2024) · Statistics in Medicine · doi:10.1002/sim.10292 · Cited by 8
“Imputation methods, such as reference-based mean imputation [25], could be explored in the future to evaluate their impact on model performance and assumptions.”
Self-citationGutiérrez‐Jiménez, E., Rasmussen, P. M., Mikkelsen, I. K., Kura, S., Fruekilde, S. K., Hansen, B. B., Bordoni, L., Carlsen, J., Palmfeldt, J., Boas, D. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70023 · Cited by 9
“5,6 This highlights the need to identify and target early disease mechanisms manifesting long before symptoms arise.”
Advancements in ultrasound-mediated drug delivery for central nervous system disorders
Chuang, C.-F., Phan, T.-N., Fan, C., Le, T.-T. V., & Yeh, C. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2438188 · Cited by 10
“Other monoclonal antibodies including gantenerumab [80] and crenezumab [81] are under clinical investigation, highlighting the ongoing therapeutic potential of these agents in addressing Aβ plaque aggregation in neurodegenerative diseases.”
Jovalekic, A., Bullich, S., Roé-Vellvé, N., Kolinger, G. D., Howard, L. R., Elsholz, F., Lagos‐Quintana, M., Blanco-Rodriguez, B., Pérez-Martínez, E., Gismondi, R., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17121648 · Cited by 7
“The changes in amyloid burden were determined using established quantitative methods, such as the Centiloid approach [33,34,96,97], or with visual assessment [98].”
InfluentialMeasuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?
Lanctôt, K. L., Jönsson, L., Atri, A., Paulsen, R., Mattke, S., Hahn‐Pedersen, J. H., Polavieja, P., Maltesen, T., León, T., Gustavsson, A., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70081 · Cited by 11
Chen, C. D., Franklin, E. E., Li, Y., Joseph‐Mathurin, N., Burns, A., Hobbs, D. A., McCullough, A. A., Schultz, S. A., Xiong, C., Wang, G., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02890-7 · Cited by 9
Self-citationAdvances of therapeutic strategies for Alzheimer’s disease
Guo, X., Yue, R.-Z., Cui, Z., Wang, S., Jia, T., Li, W., Zhang, W., Shan, L., & Li, C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13456-8 · Cited by 10
Advances in the drug treatment of Alzheimer’s disease: pathophysiology and mechanisms of action
Nowell, J., Crook, H., de Leon, M. J., & Edison, P. (2026) · BMJ · doi:10.1136/bmj-2023-078881 · Cited by 8
Reduced GLP-1R availability in the caudate nucleus with Alzheimer’s disease
Barrett, E., Ivey, G., Cunningham, A., Coffman, G., Pemberton, T., Lee, C. M., Patra, P., Day, J. B., Lee, P. H. U., & Shim, J. W. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1350239 · Cited by 9
Neve, A., Das, B., Wojtowicz, J., Huang, Z., Bullain, S., Watkin, M., Lott, D., Bittner, T., Delmar, P., Klein, G., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240221 · Cited by 8
Self-citationCai, Y., Huang, G., Ren, M., Chai, Y., Huang, X., & Yan, T. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03555-0 · Cited by 7
Siemers, E., Feaster, T., Sethuraman, G., Sundell, K. L., Skljarevski, V., Cline, E. N., Zhang, H., Jerecìć, J., Honig, L. S., Salloway, S., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100005 · Cited by 8
“Phase 3 studies for gantenerumab resulted in relatively modest reductions in amyloid plaque load and some improvement in AD biomarkers, but no statistically significant effect on clinical progression [ 19 ].”
Self-citationLozupone, M., Dibello, V., Resta, E., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Mollica, A., Berardino, G., et al. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2500752 · Cited by 9
“…lack of treatment effects on tau pathology as measured by tau PET for certain amyloid-targeting antibodies (e.g. donane-mab [12] and gantenerumab [75]), the robust and consistent reductions in fluid biomarkers of tau may primarily reflect amyloid plaque removal, leading to decreased secretion of…”
Sobral, M. V. S., Soares, V. G., Gonçalves, O. R., de Abreu, V. S., Bendaham, L. C. A. R., Batista, B. L. L., & dos Santos, M. A. R. (2024) · Archives of Gerontology and Geriatrics Plus · doi:10.1016/j.aggp.2024.100016 · Cited by 7
Ion transporter cascade, reactive astrogliosis and cerebrovascular diseases
Rahman, M. S., Islam, R., & Bhuiyan, M. I. H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1374408 · Cited by 10
Lecanemab for Alzheimer Disease: Is It Worth It?
Nelson, S. E., & López, O. L. (2024) · Neurology · doi:10.1212/wnl.0000000000209265 · Cited by 9
What the gantenerumab trials teach us about Alzheimer's treatment
Schneider, L. S. (2023) · New England Journal of Medicine · doi:10.1056/nejme2310903 · Cited by 6
Anti-Amyloid Drugs for Alzheimer’s Disease: Considering the Role of Depression
Moyano, B. P., Zullo, L., Rouaud, O., Vandel, P., von Gunten, A., & Allali, G. (2024) · Neurodegenerative Diseases · doi:10.1159/000541783 · Cited by 7
Kim, E. J., Park, S., Schuessler, B. P., Boo, H., Cho, J., & Kim, J. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116081 · Cited by 10
Relationship between efficacy and preferential targeting of soluble Aβ aggregates
Kaplan, J. M., Gibbs, E., Coutts, J. A., Zhao, B., Mackenzie, I. R., Plotkin, S. S., & Cashman, N. R. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70184 · Cited by 10
Pomara, N., & Imbimbo, B. P. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13684 · Cited by 6
Evidence-based strategies to prevent cognitive decline in older people
Flicker, L. A. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108062 · Cited by 8
Zhang, Y., Yu, W., Zhang, L., & Li, P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2396911 · Cited by 6
“Gantenerumab, a conformational antibody, selectively binds to cerebral Aβ aggregates via two binding sites at Aβ3-12 in the N-terminus and the middle region [15,16].”
Yang, Y., Qiu, H., Fan, Y., Zhang, Q., Qin, H., Wu, J., Zhang, X., Liu, Y., Zhou, R., Zhang, Q., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01584-8 · Cited by 8
“Anti-Aβ mAbs targeting different aggregation forms of Aβ have shown distinct plaque-clearing effects and clinical efficacy in the treatment of AD [7–11].”
BackgroundAssociation between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf089 · Cited by 7
Inadequate Reporting of Harm From Randomized Clinical Trials in Top Medical Publications
Zheng, R., Tao, L., Sun, Y., Shang, H., & Levine, M. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70006 · Cited by 9
Implementation of Statistical Innovation in a Pharmaceutical Company
Rufibach, K., Wolbers, M., Devenport, J. N., Yung, G., Harbron, C. G., Bedding, A. W., Huang, Z., Lin, R., Pang, H., Bové, D. S., et al. (2024) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2024.2327291 · Cited by 5
Yang, Z., Jiang, X., & Gao, J. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125069 · Cited by 5
Development and Validation of a 18 F-Flortaucipir PET Visual Stratification Method
Tunali, I., Wang, J., Arora, A., Kim, M. J., Shcherbinin, S., Pontecorvo, M. J., & Iaccarino, L. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268700 · Cited by 5
Japanese participant data from three gantenerumab trials in early Alzheimer's disease
Asada, T., Thanasopoulou, A., Delmar, P., Wojtowicz, J., Smith, J., Yoshiyama, Y., Yokoi, K., Watanabe, C., Isozaki, M., Ozaki, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70192 · Cited by 5
“16 Notably, common baseline characteristics of those in the global population of the GRADUATE studies who attained an amyloid-negative status included alowerbodyweight,loweramyloidload,andanearlierdiseasestage.”
Self-citationLiu, Y., Chen, S., Li, S., Pei, Z., Fan, S., & Guo, Y. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251362444 · Cited by 9
From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer’s Disease Landscape
Bougea, A. M., Debasa‐Mouce, M., Gulkarov, S., Castro‐Mosquera, M., Reiss, A. B., & Ouro, A. (2025) · Medicina · doi:10.3390/medicina61081462 · Cited by 8
“Phase 2 trials for semorinemab, gosuranemab, and tilavonemab (target class: Tau) are investigating monoclonal antibodies that do not exhibit any appreciable therapeutic effect [25,27,28,30–32].”
Wei, Y., & Li, H. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70017 · Cited by 5
“Among those studies, six demonstrated a significant increase in incidence among the intervention group (Bateman et al. 2023; Ostrowitzki et al. 2017; Sims et al. 2023; van Dyck et al. 2023), one demonstrated a nonsignificant increase (Ostrowitzki et al. 2022), and four studies demonstrated a…”
InfluentialVillarejo‐Galende, A., González‐Sánchez, M., Hilario, A., Velasco, S. L., Morenas‐Rodríguez, E., Muñoz-García, M. I., Ramos‐González, A., Pérez-Martínez, D. A., & Blanco-Palmero, V. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251404505 · Cited by 6
“8 A signi fi cant challenge associated with A β -targeting immunotherapies is the occurrence of amyloid-related imaging abnormalities (ARIAs).”
ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner
Steward, A., Dewenter, A., Hirsch, F., Roemer, S. N., Zhu, Z., Dehsarvi, A., Biel, D., Klonowski, M., Frontzkowski, L. K., Palleis, C., et al. (2025) · Brain · doi:10.1093/brain/awaf463 · Cited by 6
Singh, A. S., Naqvi, A. R., & Chanu, M. T. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.050 · Cited by 7
Zhang, B., Yu, X., & Zhang, X. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08893-w · Cited by 6
Merkel, J., Perneczky, R., Jessen, F., Frölich, L., Jansen, O., Peters, S., Berg, D., Schulz, J. B., & Bartsch, T. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02022-7 · Cited by 5
“3C and D) [3, 4, 18, 31–33].”
Xiao, B., & Tan, E. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1559 · Cited by 5
Devanarayan, V., Llano, D. A., Hu, Y. H., Hampel, H. J., Kramer, L. D., Dhadda, S., & Irizarry, M. C. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12621 · Cited by 6
“29 Recent publications on pTau181 and other isoforms 5,7,25 have focused on predicting long-term progression ( > 3 years) using research cohorts, emphasizing population-level associations over individual predictive performance.”
BackgroundDevanarayan, V., Ye, Y., Zhu, L., Tian, L., Kramer, L. D., Irizarry, M. C., & Dhadda, S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70045 · Cited by 8
Greeley, D. R., Nash, M., Herskowitz, B., Kim, F., Rock, J., Prins, N., Kim, S., Xi, T., Busam, J. A., Tete, B., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100337 · Cited by 10
Chern, H., Caruso, G., Desaire, H., & Jarošová, R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00596 · Cited by 10
Antiamyloid treatment for dementia: concerns outweigh hopes
Flicker, L. A. (2025) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000001021 · Cited by 7
Gantenerumab in Early Alzheimer’s Disease
Bateman, R. J., Smith, J., & Doody, R. S. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2314291 · Cited by 5
Self-citationKönig, T., Silvaieh, S., Parvizi, T., Wurm, R., Goeschl, S., Uhlik, E., Farr, C. V., Berger–Sieczkowski, E., Untersteiner, H., Zimprich, A. A., et al. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101517 · Cited by 4
Duncan, G. B., Dickson, S. P., Kaplan, J. M., Johnson, S. B., Duke, T. M., Dayley, C. W., Hendrix, S. B., Altstiel, L. D., & Mallinckrodt, C. H. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70183 · Cited by 5
The roles of biomarkers in Alzheimer's disease clinical trials
Cummings, J. L., Sharma, S., DeAndrea, G., Osse, A. M. L., & Ortiz, A. A. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00811 · Cited by 5
“Gantenerumab, an anti-amyloid MAB that did not achieve its primary endpoint, had TRAC in 28 % and 26.8 % of participants in the Phase 3 Graduate I and II trials [57].”
InfluentialSelf-citationTariot, P. N., Lopera, F. J., Ríos‐Romenets, S., Sink, K. M., Giraldo, M., Acosta‐Baena, N., Villegas, G., Espinosa, A. C., Castaño, M. L., Muñoz, C. G., et al. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00426-0 · Cited by 8
Self-citationAlzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 6
Scouarnec, L. L., Bouteloup, V., van der Veere, P. J., van der Flier, W. M., Teunissen, C. E., Verberk, I. M. W., Planche, V., Chêne, G., & Dufouil, C. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01595-5 · Cited by 6
Zavarella, M., Cecchetti, G., Rugarli, G., Ghirelli, A., Bottale, I., Orlandi, F., Spinelli, E. G., Santangelo, R., Caso, F., Calloni, S. F., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12910-x · Cited by 4
Costa, A. C. S. (2024) · Brain Sciences · doi:10.3390/brainsci14111084 · Cited by 5
“The results of the GRADUATE 1 and 2 trials of gantenerumab came out on 13 November 2022 [56].”
InfluentialJeong, S. Y., Suh, C. H., Lim, J., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2024.0140 · Cited by 4
Mostafa, A., Tiu, S., Khan, F. A., & Baig, N. A. (2025) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_547_24 · Cited by 7
“…on aducanumab (EMERGE and ENGAGE), [12] three on solanezumab (EXPEDITION 1, 2, and 3), [13,14] two on bapineuzumab (STUDY 301 and STUDY 3000), [15,16] three on gantenerumab (SCARLET ROAD, GRADUATE I and II), [17,18] one on donanemab (TRAILBLAZER‑ALZ‑2) [19] and two on crenezumab (CREAD 1 and 2).”
InfluentialNoguchi‐Shinohara, M., & Ono, K. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4604-24 · Cited by 4
Bateman, R. J., Li, Y., McDade, E., Guerra, J. J. L., Clifford, D. B., Atri, A., Mills, S. L., Santacruz, A. M., Wang, G., Supnet, C. B., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4906344 · Cited by 5
Self-citationFertan, E., Lam, J. Y. L., Albertini, G., Dewilde, M., Wu, Y., Akingbade, O. E. S., Böken, D., English, E. A., Strooper, B. D., & Klenerman, D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.11.617910 · Cited by 5
Recent perspectives on side effects of drugs used in the treatment of Alzheimer's disease
D’Souza, M. S., Hunsicker, H., Pham, L. T. T., Hussain, A. R., & Ray, S. D. (2024) · Side effects of drugs annual · doi:10.1016/bs.seda.2024.07.003 · Cited by 3
Chandler, J. M., Lansdall, C. J., Ye, W., McDougall, F., Belger, M. A., Toth, B., Mi, X., Sink, K. M., & Atkins, A. S. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100261 · Cited by 3
An, D., Zou, X., & Xu, Y. (2025) · Current Neuropharmacology · doi:10.2174/011570159x391766250806091602 · Cited by 3
“The other 6 monoclonal antibodies were IgG1 [54-59].”
Wei, H., Zhang, G., Xu, Y., Zhao, A., Zheng, Y., Shao, Y. W., Yang, L., Wang, J., & Jiang, X. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157238 · Cited by 4
Comparison of amyloid PET acquired through standardized and unstandardized protocols
Cody, K. A., Sokolowski, A., Guerra, L. M., Insel, P. S., Jagust, W., Harrison, T. M., & Mormino, E. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70697 · Cited by 4
“37 Although the CL scale 28 improves our ability to compare values across thefourwidelyusedamyloidPETligands,thereducedvariabilityofCLs present within the A– group for PiB across all three cohorts relative to FBB and FBP suggests that a lower CL threshold for positivity may be more appropriate for…”
Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West
Curd, B. C., Zubrick, C., Brown, C. J. C., Sorweid, M. K., Dehoney, S. B., Anzai, Y., Minoshima, S., Parks, A. L., & Frost, N. A. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70251 · Cited by 9
“7,17,22,37 This highlights that ARIAs are strongly associated with amyloid deposition regardless of treatment.”
Otani, K., Ishihara, H., Nakamura, T., & KAWABE, K. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.04.006 · Cited by 3
Nithya, R., & Ramanathan, M. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025054214 · Cited by 4
Joseph, C. R. (2024) · Diagnostics · doi:10.3390/diagnostics14070726 · Cited by 2
“Here-to-fore therapeutic efforts at mitigating Alzheimer’s disease have focused on late-disease-stage removal of toxic protein end products ( β Amyloid) with limited effect and great expense [1,2].”
BackgroundFluid Biomarker Changes After Amyloid-β–Targeting Drugs
Ossenkoppele, R., & Teunissen, C. E. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.1103 · Cited by 3
Puzzo, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240406 · Cited by 3
Dougnon, G., Otsuka, T., Nakamura, Y., Sakai, A., Yamanaka, T., Matsui, N., Nakahara, A., Ito, A., Hatano, A., Matsumoto, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.10.579739 · Cited by 3
Asada, T., Kakuma, T., Tanaka, M., Araki, W., Lebowitz, A., Momose, T., & Matsuda, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251324222 · Cited by 2
“Over the past decade, several clinical trials of Anti-A β DMDs including aducanumab, 20 donanemab, 21 ganteneru-mab, 22 and lecanemab 23 have accumulated data sets of A β -PET and brain perfusion 99m Tc-ECD SPECT imaging.”
Is screening for Alzheimer’s disease ready for prime time? Ask Wilson and Jungner
Chatanaka, M. K., Loren, M., & Diamandis, E. P. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2533860 · Cited by 3
“As discussed earlier, monclonal ant-amyloid antibodies like Lecanemab and other similar agents have been developed and some are already FDA-approved for the treatment of AD [77–80].”
Active immunization: A novel therapeutic strategy for treating Alzheimer's disease
Mazahir, F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178288 · Cited by 4
The Cerebral Clearance Cascade as a Driver of Alzheimer’s Disease Progression
Izrael, M., & Frenkel, O. M. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad3010001 · Cited by 2
Chen, T., Hutchison, R. M., Rubel, C. E., Murphy, J. M., Xie, J., O'Gorman, J. T., Dent, G. W., Molenberghs, G., Sormani, M. P., Hendrix, S. B., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100458 · Cited by 6
“For example, when taken separately, gantenerumab treat-ment in the GRADUATE I and GRADUATE II trials failed to produce a significant clinical effect on the CDR-SB [63,84].”
Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum
Hall, B. J., Aumont, É., Hosseini, S. A., Arias, J. F., Boré, A., Bezgin, G., Trudel, L., Chan, T., Therriault, J., Macedo, A. C., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214606 · Cited by 3
Defining Alzheimer’s disease: stipulations and the ethics of diagnostic change
Michalon, R., Planche, V., Lemoine, M., Keuck, L., & Villain, N. (2026) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-337832 · Cited by 3
“32 33 Beyond scientific and clinical considerations, amyloid-based diagnosis entails significant public health and ethical implications.”
Zhai, Y., Nevian, T., Finn, D. P., & Kwakowsky, A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00025-0 · Cited by 2
The aggregation of amyloid-β: from condensation, nucleation, and conformation to targeting therapy
Chen, B., Chen, T., Sun, Z., Liu, L., Jia, Y., Ji, Y., Wang, J., Sun, F., & Huang, Y. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124397 · Cited by 3
The mechanisms and strategies for Alzheimer’s disease prevention: An update
Han, M., Wang, N., Song, M., Liu, C., Wu, Y., Yin, J., Jin, L., Jin, W., & Gao, Z. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.007 · Cited by 3
“Subgroup analyses revealed an 18% slowing of cognitive decline in APOE4 non-carriers, although this drug has not yet received regulatory approval for the treatment of AD 65,66 .”
Lecanemab use in Chinese patients with Alzheimer's disease: a 12‐month multicenter real‐world study
Wu, H., Chen, Q., Fang, M., Hui⁃dong, T. A. N. G., Liu, H., Liu, J., Zhang, J., Chi, L., Liu, S., Xin, J., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71702 · Cited by 4
“28,35,36 37–39 The ApoE ε 4 allele is associated with both higher total A β levels and greater vascular A β deposition.”
Abdelaziz, A. M., & Eltyar, F. S. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110777 · Cited by 2
Fillit, H. M., Assunção, S. S., Majda, T., Ng, C. D., To, T. M., Abbass, I. M., Raimundo, K., Wallick, C. J., & Tcheremissine, O. V. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.115 · Cited by 2
Alzheimer's Disease Clinical Trials: What Have We Learned From Magnetic Resonance Imaging
By, S., Kahl, A., & Cogswell, P. M. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29462 · Cited by 4
“3,20,21 Generally, MRI safety monitoring is performed more frequently at the beginning of the trial, and then tapered off to every 3 – 6 months, barring no reports of adverse events.”
Metadata
- Authors
- Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., Wojtowicz, J., Blennow, K., Bittner, T., Black, S. E., Klein, G., Boada, M., Grimmer, T., Tamaoka, A., Perry, R. J., Turner, R. S., Watson, D., Woodward, M., Thanasopoulou, A., Lane, C., Baudler, M., Fox, N. C., Cummings, J. L., Fontoura, P., & Doody, R. S.
- Affiliations
- Washington University in St. Louis (US)
- Roche (United Kingdom) (GB)
- University of Southern California (US)
- F. Hoffmann-La Roche AG (CH)
- Brown University (US)
- Sahlgrenska University Hospital (SE)
- University of Toronto (CA)
- From the Department of Neurology, Washington University School of Medicine, St. Louis (R.J.B.); Roche Products, Welwyn Garden City (J.S., C.L.), and the Department of Brain Sciences, Faculty of Medicine, Imperial College London (R.J.P.), and the Dementia Research Centre, Department of Neurodegenerative Disease, and the U.K. Dementia Research Institute, Queen Square Institute of Neurology, University College London (N.C.F.), London — all in the United Kingdom; the Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego (M.C.D.), and Genentech, South San Francisco (T.B., R.S.D.) — both in California; F. Hoffmann–La Roche, Basel, Switzerland (P.D., R.A., J.W., T.B., G.K., A. Thanasopoulou, M. Baudler, P.F., R.S.D.); Butler Hospital and Warren Alpert Medical School, Brown University, Providence, RI (S.S.); the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, and the Clinical Neurochemistry Laboratory, Sahlgrens...
- TUM Klinikum (DE)
- University of Tsukuba (JP)
- UCL Queen Square Institute of Neurology (GB)
- Georgetown University (US)
- Austin Hospital (AU)
- UK Dementia Research Institute (GB)
- University of Nevada, Las Vegas (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-11-16
- Volume
- 389
- Issue
- 20
- Pages
- 1862-1876
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10794000
- OpenAlex
- W4388688059
- Cited by
- 314
- References
- 30
- Citations by year
- 2026: 91 · 2025: 120 · 2024: 100 · 2023: 3
- FWCI
- 55.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- HAL (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- gantenerumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, mild cognitive impairment, mild dementia, amyloid PET, cerebrospinal fluid biomarkers, cognitive decline, treatment discontinuation, safety and tolerability, subcutaneous administration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Antibodies, Monoclonal, Humans, Middle Aged, Amyloid beta-Peptides, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.